Molecular mechanisms for vascular complications of targeted cancer therapies.

Gopal, Srila; Miller, Kenneth B; Jaffe, Iris Z

Gopal, Srila; Miller, Kenneth B; Jaffe, Iris Z.

Affiliation

Gopal S; Department of Medicine, Division of Hematology/Oncology, Tufts Medical Center, Boston, MA 02111, U.S.A. Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA 02111, U.S.A. srilagopal@gmail.com ijaffe@tuftsmedicalcenter.org.
Miller KB; Department of Medicine, Division of Hematology/Oncology, Tufts Medical Center, Boston, MA 02111, U.S.A.
Jaffe IZ; Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA 02111, U.S.A. Department of Medicine, Division of Cardiology, Tufts Medical Center, Boston, MA 02111, U.S.A. srilagopal@gmail.com ijaffe@tuftsmedicalcenter.org.

Clin Sci (Lond) ; 130(20): 1763-79, 2016 10 01.

Article in En | MEDLINE | ID: mdl-27612952

Subject(s)

Antineoplastic Agents/adverse effects; Cardiovascular Diseases/etiology; Molecular Targeted Therapy/adverse effects; Neoplasms/drug therapy; Animals; Antineoplastic Agents/therapeutic use; Cardiovascular Diseases/genetics; Cardiovascular Diseases/metabolism; Humans; Neoplasms/genetics; Neoplasms/metabolism

Key words

VEGF inhibitors; targeted cancer therapy; tyrosine kinase inhibitors; vascular disease

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Molecular Targeted Therapy / Neoplasms / Antineoplastic Agents Aspects: Patient_preference Limits: Animals / Humans Language: En Journal: Clin Sci (Lond) Year: 2016 Document type: Article Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google